TL;DR:
- Can-Fite partners with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI and ML.
- Focus on creating A3 adenosine receptor drug agonists for faster and cost-effective drug development.
- CPI utilizes MegaSyn generative AI for molecule design; Can-Fite handles testing and validation.
- Prof. Pnina Fishman emphasizes delivering small molecule drug candidates efficiently.
- Sean Ekins, CEO of CPI, is excited about integrating technology for novel and selective molecules.
Main AI News:
In a groundbreaking move for the pharmaceutical industry, Can-Fite BioPharma Ltd. has entered into a visionary agreement with Collaborations Pharmaceuticals, Inc. (CPI), marking a significant stride toward the development of cutting-edge anti-cancer drugs. This partnership leverages the power of artificial intelligence (AI) and machine learning (ML) techniques, promising to revolutionize the landscape of oncology drug development.
The primary objective of this collaboration is to engineer next-generation A3 adenosine receptor drug agonists, poised to substantially expedite the time and reduce the costs associated with bringing such transformative drugs to market.
CPI, armed with its state-of-the-art MegaSyn generative AI method, will harness the capabilities of AI and ML tools to craft entirely new molecules meticulously tailored for the A3AR target, identified by Can-Fite. Furthermore, CPI will undertake the complex chemical synthesis of these newly designed molecules, with the ultimate aim of birthing a portfolio of innovative and robust anti-cancer drug candidates.
Can-Fite, on the other hand, will spearhead the crucial task of rigorously testing the biological anti-cancer effects of these novel candidates. Their role also extends to validating the molecular mechanisms that underpin these chemically synthesized drug candidates, ensuring a comprehensive understanding of their potential.
Prof. Pnina Fishman, Executive Chairman and CSO at Can-Fite, articulated the significance of this venture, stating, “Our vision is to deliver in silico small molecule drug candidates in a better and faster way to patients via a collaboration with Collaborations Pharmaceuticals. Our accumulated experience of bringing anti-cancer drugs that target the A3AR from lab to patients will be implemented into this AI drug development project.“
Sean Ekins, PhD, DSc., CEO and founder of Collaborations Pharmaceuticals, Inc., expressed his enthusiasm, saying, “We are delighted that Can-Fite chose our team of experts for this AI-led drug discovery collaboration and look forward to demonstrating what our technology can do. We also look forward to complementing their outstanding scientific approach with our integrated technology platform and ability to generate novel and selective molecules.”
Can-Fite BioPharma Ltd. stands as an advanced clinical stage drug development company, equipped with a platform technology specifically designed to address multi-billion-dollar markets in the treatment of cancer, liver conditions, and inflammatory diseases.
Collaborations Pharmaceuticals, Inc. is the innovator behind MegaSyn, a pioneering generative drug design tool. They have also developed Assay Central software for data curation and machine learning, in addition to curating model collections such as MegaTox, MegaTrans, and MegaPredict. This strategic partnership marks a significant milestone in the quest for cutting-edge anti-cancer therapies, fueled by the synergy of Can-Fite’s expertise and CPI’s innovative technology.
Conclusion:
This collaboration signifies a significant advancement in the pharmaceutical market. By harnessing the power of AI and ML, Can-Fite and CPI are poised to accelerate the development of anti-cancer drugs, potentially transforming the landscape of oncology treatment. This innovative partnership reflects a commitment to delivering more efficient and effective solutions to patients, with broad implications for the entire pharmaceutical industry.
